Products
Lornoxicam was commercially available in the form of film-coated tablets (Xefo). It had been approved in many countries since 1997. It was discontinued in 2020.
Structure and properties
Lornoxicam (C13H10ClN3O4S2, Mr = 371.82 g/mol) belongs to the oxicam group and is practically insoluble in water. Lornoxicam is a chlorinated derivative of tenoxicam (Tilcotil).
Effects
Lornoxicam (ATC M01AC05) has analgesic, antipyretic, and anti-inflammatory properties. The effects are due to inhibition of cyclooxygenases-1 and 2- and prostaglandin synthesis. Unlike its precursor tenoxicam, lornoxicam has a short half-life of three to four hours.
Indications
For symptomatic treatment of pain and inflammation associated with inflammatory and degenerative rheumatic diseases, such as osteoarthritis and rheumatoid arthritis.
Dosage
According to the drug label. Tablets are usually taken two to three times daily before meals.
Contraindications
Numerous precautions and possible drug interactions must be observed before use. Full details can be found in the drug label.
Adverse effects
The most common possible adverse effects include digestive disturbances, liver dysfunction, skin rash, dizziness, headache, migraine, taste disturbances, sweating, leg cramps, paresthesias, tremor, depression, insomnia, and fatigue. As with all NSAIDs, serious side effects are rarely possible.
